.After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma crease, occupying the top scientific research area at Sanofi.Quigley will certainly start Sept. 30 as the French Big Pharma's main clinical officer and worldwide head of investigation, Sanofi told Fierce Biotech in an emailed declaration.Quigley is replacing Frank Nestle, M.D., that left behind Sanofi this springtime in the middle of an international overhaul of the company's R&D unit. Nestle, that invested eight years along with the pharma, leapt over to Deerfield Management, where he presently works as a partner on the therapies crew and chief executive officer of the agency's curative discovery as well as development functions.
Quigley is going to participate in Sanofi coming from a San Francisco-based biotech that's in stealth, depending on to his LinkedIn account. He is actually currently noted as the business's co-founder, head of state as well as chief executive officer.Since August 2021, Quigley has actually functioned as a project companion at SV Wellness Investors, a health care fund manager with existing expenditures in biotechs including BioAge, Cerevance, Dualitas Therapies and Nimbus Rehabs, among others. Quigley in the past held the best location at Dualitas, a biotech that remains in secrecy, depending on to STAT.The prospective Sanofi innovator additionally previously helmed Therini Bio, an immunotherapy biotech working to cultivate therapies for neurodegenerative ailments driven through vascular problems.Prior to investing the last handful of years in biotech, Quigley has an also longer performance history in Major Pharma, very most just recently serving as Gilead's senior vice head of state of research the field of biology till the summertime of 2021. Prior to that, he clocked in greater than four years all over numerous leadership roles at Bristol Myers Squibb and also served as a scientific director at Johnson & Johnson's Janssen arm just before that.Sanofi stated Quigley's objective in his new role would certainly be actually to "optimize our possibility of success by means of optimum cooperations throughout our association as well as past, carrying best-in-class advancement in addition to cultivating and sourcing new industry-leading talent along with a commitment to variety," according to an interior memo secured by STAT.